The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.

Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in ...

Senti Bio (SNTI)sciences announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration ...

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...

费城 - 专注于巨噬细胞治疗的生物制药公司Carisma Therapeutics Inc. (NASDAQ:CARM)今日宣布对其运营进行重大重组。该公司目前市值3,335万美元，股价接近52周低点。公司将停止CT-0525项目的开发，并裁减34%的员工，以集中精力发展其体内巨噬细胞工程平台。这一战略转变旨在开发纤维化、肿瘤学和自身免疫疾病的治疗方法。根据 InvestingPro ...

After three unsuccessful rounds of chemotherapy back in New Zealand, 57-year-old New Zealander Dale De Penning decided to ...

As the Circle 7 Toy Story 3 was further into production than the studio's other films, a greater volume of material corresponding to the film (such as concept art, character designs and a brief ...

相关研究为肿瘤浸润性CAR-T细胞的进化提供了独特的见解。 贝勒医学院和德克萨斯儿童癌症中心的科学家们领导了一项针对表达glypican-3 （GPC3）的实体肿瘤的新型免疫治疗方法的首次人体研究。该研究小组在《Nature》杂志上发表了一篇题为《Interleukin-15-armoured GPC3 ...

Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...